Adaptive Biotechnologies (NASDAQ: ADPT) reported Q2 EPS of ($0.25), $0.11 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $71.55 million versus the consensus estimate of $65.75 million.

For earnings history and earnings-related data on Adaptive Biotechnologies (ADPT) click here.